CASI Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-28.
CASI Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 28, 2026. The filing reports $5M sold. Its industry group is Pharmaceuticals. It names Wei-Wu He (Director), Zhenbo Su (Director), Thomas Folinsbee (Director) (SEC Form D, January 28, 2026).
Sell to companies like CASI Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-28 · the record
Pitching, partnering or investing alongside them? See who really runs and owns CASI Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind CASI Pharmaceuticals, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when CASI Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when CASI Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch CASI Pharmaceuticals, Inc. →Get the full cited report on CASI Pharmaceuticals, Inc.
What the filing shows about CASI Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CASI Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for CASI Pharmaceuticals, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on CASI Pharmaceuticals, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $5M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Wei-Wu He is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
Zhenbo Su is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
Thomas Folinsbee is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
Alexander Wu is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
Xuebo Zeng is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Wei Gao is named as General Counsel on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Kun Qian is named as Global Controller on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Chunhua Wang is named as Chief Operating Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Hai Huang is named as Global Chief Commercial Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Wei (Larry) Zhang is named as Vice President on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer.
Alexander Zukiwski is named as Chief Medical Officer on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Executive Officer, Director.
David Cory is named as Chief Executive Officer and a member of the Board of Directors on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
On the filing as: Director.
James Huang is named as Non-Executive Chairman of the Board on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
Barbara Krebs-Pohl is named as Director on the Form D that CASI Pharmaceuticals, Inc. filed with the SEC on 28 January 2026, one of 14 people that filing names.
14 people named on the filing — 7 holding an executive role and 7 as directors only.
Named as of the 2026-01-28 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 14 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about CASI Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on CASI Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CASI Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist CASI Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind CASI Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for CASI Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/casi-pharmaceuticals-inc-form-d-26000006